China Updates Export Controls on Technologies, Adds Gene Editing to List
The Ministry of Finance (MOF) has released an updated notification regarding technologies banned and restricted...
Novartis’ Kisqali Receives NMPA Approval for Premenopausal Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced receiving marketing approval from the National Medical...
Fosun Pharma’s Comirnaty Bivalent Vaccine Approved in Macau for Booster Shots
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its Comirnaty...
HuidaGene Receives FDA IND Approval for Ophthalmology Gene Therapy HG004
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced receiving Investigational New Drug (IND) approval from...
HutchMed Signs Licensing Deal with Takeda for Global Fruquintinib Development
Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has announced a licensing deal with Japanese...
Tianjin-Based Protein T Raises RMB 100 Million in Series A Financing
Tianjin-based biotech Protein T, focused on multi-omics research, has reportedly raised close to RMB 100...
Ascletis Receives IND Approval for ASC10 in Monkeypox Treatment
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving Investigational New Drug (IND) approval from...
Legend Biotech’s Carvykti Meets Primary Endpoint in CARTITUDE-4 Phase III Study
Legend Biotech (NASDAQ: LEGN) has released positive data from the CARTITUDE-4 Phase III study, evaluating...
CSPC’s Octreotide Long-Acting Injection Approved for Acromegaly Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
BeiGene’s Brukinsa Approved by FDA for Chronic Lymphocytic Leukemia
China-based BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the US FDA has...
Dartsbio Pharmaceuticals Secures RMB 100 Million in Series B Financing
Guangdong-based antibody drug developer Dartsbio Pharmaceuticals has reportedly raised over RMB 100 million in a...
CNBG-Virogin’s Omicron-Targeted mRNA Vaccine Approved for Clinical Trials
CNBG-Virogin Biotech (Shanghai) Co., Ltd has announced obtaining clinical trial approval from the National Medical...
Hepagene’s FXR Agonist HPG1860 Shows Positive Phase IIa Data in NASH Study
China-based liver disease specialist Hepagene Therapeutics (HK) Limited has revealed positive data from the Phase...
Ascentage Pharma Raises HKD 550 Million in Secondary Offering for Pipeline Expansion
Suzhou-based Ascentage Pharma (HKG: 6855) is set to conduct a secondary offering of 22.5 million...
BMS’s Opdivo Approved in China for Neoadjuvant Therapy in Urothelial Carcinoma
US-based Bristol-Myers Squibb (BMS, NYSE: BMY) has secured another new indication approval in China for...
NHSA Updates 2022 National Reimbursement Drug List with 2,967 Drug Varieties
The National Healthcare Security Administration (NHSA) has revealed the results of the 2022 National Reimbursement...
Harbour BioMed Receives FDA Approval for HBM1007 Clinical Study
China-based Harbour BioMed (HKG: 2142) has announced receiving approval from the US FDA to initiate...
Joincare’s Biosimilar Tocilizumab Approved for Marketing in China
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that its subsidiary Zhuhai...
CANbridge Pharmaceuticals Initiates Phase II Dosing for CAN103 in Gaucher Disease
China-based CANbridge Pharmaceuticals, Inc. (HKG: 1228) has announced the first patient dosing in the Phase...